These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34030459)

  • 41. Convenience, efficacy, safety, and durability of INSTI-based antiretroviral therapies: evidence from the Italian MaSTER cohort.
    Rich SN; Nasta P; Quiros-Roldan E; Fusco P; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G;
    Eur J Med Res; 2023 Aug; 28(1):292. PubMed ID: 37596688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
    Marcelin AG; Grude M; Charpentier C; Bellecave P; Le Guen L; Pallier C; Raymond S; Mirand A; Bocket L; Fofana DB; Delaugerre C; Nguyen T; Montès B; Jeulin H; Mourez T; Fafi-Kremer S; Amiel C; Roussel C; Dina J; Trabaud MA; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Maillard A; Ferre V; Descamps D; Calvez V; Flandre P;
    J Antimicrob Chemother; 2019 May; 74(5):1368-1375. PubMed ID: 30789205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
    Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G
    J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
    Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
    J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
    Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
    J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting.
    Clemente T; Galli L; Poli A; Papaioannu Borjesson R; Bresciani L; Muccini C; Canetti D; Candela C; Bossolasco S; Hasson H; Castagna A; Spagnuolo V
    Int J Antimicrob Agents; 2023 Aug; 62(2):106897. PubMed ID: 37343809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.
    Lambert-Niclot S; Boyd A; Fofana D; Valin N; Wirden M; Meynard JL; Palich R; Agher R; Valantin MA; Calvez V; Katlama C; Girard PM; Marcelin AG; Morand-Joubert L
    Open Forum Infect Dis; 2019 May; 6(5):ofz177. PubMed ID: 31123690
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.
    Zalla LC; Cole SR; Eron JJ; Adimora AA; Vines AI; Althoff KN; Silverberg MJ; Horberg MA; Marconi VC; Coburn SB; Lang R; Williams EC; Gill MJ; Gebo KA; Klein M; Sterling TR; Rebeiro PF; Mayor AM; Moore RD; Edwards JK
    JAMA; 2023 Jan; 329(1):52-62. PubMed ID: 36594946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice.
    Santoro MM; Di Carlo D; Armenia D; Zaccarelli M; Pinnetti C; Colafigli M; Prati F; Boschi A; Antoni AMD; Lagi F; Sighinolfi L; Gervasoni C; Andreoni M; Antinori A; Mussini C; Perno CF; Borghi V; Sterrantino G
    Antivir Ther; 2018; 23(3):249-257. PubMed ID: 28935850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
    Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
    BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.
    Karris MY; Jain S; Day TR; Pérez-Santiago J; Goicoechea M; Dubé MP; Sun X; Spina C; Daar ES; Haubrich RH; Morris S;
    HIV Clin Trials; 2017 Mar; 18(2):67-74. PubMed ID: 28134057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
    Burgos J; Moreno-Fornés S; Reyes-Urueña J; Bruguera A; Martín-Iguacel R; Raventos B; Llibre JM; Imaz A; Peraire J; Orti AJ; Dalmau D; Casabona J; Miró JM; Falcó V;
    J Antimicrob Chemother; 2022 Dec; 78(1):108-116. PubMed ID: 36308326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
    Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
    Pyngottu A; Scherrer AU; Kouyos R; Huber M; Hirsch H; Perreau M; Yerly S; Calmy A; Cavassini M; Stöckle M; Furrer H; Vernazza P; Bernasconi E; Günthard HF;
    Clin Infect Dis; 2021 Oct; 73(7):e2134-e2141. PubMed ID: 33095848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
    Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
    Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Integrase Strand Transfer Inhibitor Use During Pregnancy on Viral Suppression at Delivery and Infant Outcomes: A Statewide Retrospective Cohort Study.
    Latham AH; Nissim OA; Spitznagel MC; Kirk SE; Tarleton JL; Lazenby GB
    J Acquir Immune Defic Syndr; 2022 Apr; 89(4):448-453. PubMed ID: 35202051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.